June 24, 2023 11:04am

It’s a timing lesson risk; take a look at phase 2 and 3 clinical and partnered companies to potentially alleviate pricing menace

News: where has it been published? Here investors get the status of their investments and why of cause!

Pre-open Indications: 2 Hits and 1 Miss

Subscription is coming, it is not conscription but, an offer to join our collective of like-minded investors!  Join me … in the NO spin zone.

Never leave an investor uninformed! Framing the main takeaway … pricing, volume and machine trading creates volatility and liquidity!

The week in review

If I have learned one thing as a former research analyst in a venture and public fund, operating executive, adjunct (MBA) business school professor now a journalist; it is that your life and your portfolio are largely tied to your knowledge of price movements and questioning pricing targets.

 

The Dow closed DOWN -219.28 points (-0.65%), the S&P closed DOWN -33.56 points (-0.77%) while the Nasdaq closed DOWN -138.09 points (-1.01%)

 

Henry’omics:

We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies …

Indexes dived on Friday, ending a losing week.

‘All three major averages broke multiweek winning streaks. The S&P 500 lost about 1.4%, ending five consecutive weeks of gains. The Nasdaq dropped 1.4%, snapping an eight-week win streak and posting its worst weekly performance since March. The Dow was nearly 1.7% lower, ending a three-week positive run.” <CNBC>

Economic Data Docket: Manufacturing activity in the U.S. slowed more than expected in June. The index registered a 46.3, down from the 48.4 in May and below the 49.0 estimate, anything below 50 represents contraction. The services’ reading came in at 54.1 was a two-month low and below the 54.9 in May. The composite index came in at 53.0, below the 54.3 from the previous month but still showing expansion even though it was a three-month low.

 

Friday (6/23) … RegMed Investors’ (RMi) pre-open: “another pullback and the end to a losing week? There are more equities in risk!” … https://www.regmedinvestors.com/articles/13016

 

RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened – differences …

  • Friday’s advance/decline line opened negative at 5 up/ 29 down and 1 flat, stayed negative with 5 up/ 30 down and 0 flat at the mid-day, ending with a negative close of 9 incliners, 26 decliners and 0 flat
  • Thursday’s advance/decline line opened negative at 12 up/ 21 down and 2 flats, stayed negative with 7 up/ 28 down and 0 flat at the mid-day, ending with a negative close of 10 incliners, 24 decliners and 1 flat
  • Wednesday’s advance/decline line opened negative at 8 up/ 25 down and 2 flats, stayed negative with 16 up/ 19 down and 0 flat at the mid-day, ending with a negative close of 13 incliners, 19 decliners and 0 flat
  • Tuesday’s advance/decline line opened negative at 12 up/ 21 down and 2 flats, stayed negative with 16 up/ 18 down and 1 flat at the mid-day, ending with a positive close of 20/15 and 0 flat
  • Monday was market holiday

 

Pre-open indications: 2 Hits <Brainstorm Cell Therapeutics (BCLI -$0105), Blueprint Medicine (BPMC -$0.26)> and 1 Miss < Compass Therapeutics (CMPX -$0.13)

 

Key Metrics:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Friday, the IBB was down -1.04% and the XBI was down -1.70%
  • Thursday, the IBB was UP +0.03% and the XBI was down -0.60%
  • Wednesday, the IBB was down -0.43% and the XBI was down -0.52%
  • Tuesday, the IBB was down -0.70% and the XBI was down -0.03%
  • Monday, holiday

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Friday was up +0.53. point or +4.11% at 13.44
  • Thursday was down -0.40 point or -3.03% at 12.80
  • Wednesday was down -0.65 point or -4.68% at 13.23
  • Tuesday was down -0.30 point or -2.11% at 13.89
  • Monday, holiday

 

Closing Down (10 of 30):

  • Alnylam Pharmaceuticals (ALNY -$6.38 after Thursday’s -$4.83 after Wednesday’s +$2.30),
  • Sage Therapeutics (SAGE -$4.84 after Thursday’s -$0.62),
  • Ionis Pharmaceuticals (IONS -$1.56),
  • Ultragenyx (RARE -$1.35 after Thursday’s -$0.60 after Wednesday’s +$2.02 and Tuesday’s +$1.85),
  • Intellia Therapeutics (NTLA -$1.00 after Thursday’s +$0.13 after Wednesday’s -$1.77 and Tuesday’s -$1.29),
  • CRISPR Therapeutics (CRSP -$0.91),
  • Beam Therapeutics (BEAM -$0.72),
  • Voyager Therapeutics (VYGR -$0.46 after Thursday’s -$0.25 after Wednesday’s -$1.35 after Tuesday’s +$1.02),
  • BioLife Solutions (BLFS -$0.43),
  • Blueprint Medicine (BLMC -$0.26 after Thursday’s +$0.42 after Wednesday’s -$0.34 and Tuesday’s +$2.69)

Closing Up (9 of 9):

  • Vericel (VCEL +$0.65 after Thursday’s +$1.16 and Wednesday’s +$0.91),
  • uniQure NV (QURE +$0.31 after Thursday’s -$0.48 after Wednesday’s -$7.82),
  • Generation Bio (GBIO +$0.26 after Thursday’s +$0.42 after Wednesday’s +$0.30),
  • MiMedx (MDXG +$0.08 after Thursday’s +$0.10 after Wednesday’s +$0.42),
  • Caribou Biosciences (CRBU +$0.07 after Thursday’s +$0.09, Wednesday’s +$0.07 and Tuesday’s -$0.24),
  • Editas Medicine (EDIT +$0.05),
  • Prime Medicine (PRME +$0.04),
  • bluebird bio (BLUE +$0.02),
  • Sangamo Therapeutics (SGMO +$0.01)

 

Q2/23 – June

  • Friday closed negative with 9 incliners, 26 decliners and 0 flat
  • Thursday closed negative with 10 incliners, 24 decliners and 1 flat
  • Wednesday closed negative with 13 incliners, 22 decliners and 0 flat
  • Tuesday closed positive with 20 incliners, 15 decliners and 0 flat
  • Monday was a market holiday

 

The BOTTOM LINE: I try to keep it simple … and short!

I follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”

A losing session follows a losing week.

After stabs to the heart of share pricing – some deserved; examine the parameters of timing to foresee the apparitions of electronic and algorithmic trading … looking for gains after newest bottoms!

The only issue is the end of Q2 next week; yet, Q reporting is weeks if not a month away.

 

Investors should be considering thought and pre-emptive moves amid renewed fears of a US recession said. Inflation levels remain elevated and Fed monetary policy remains knowledgably pessimistic.

I believe, there is a great deal of money on the sidelines of people who had been scared of the coming July, a usual slow month for trading.

 

Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

Reiterating, there is VALUE out there even as electronic trading and algorithms take their toll on share pricing however, it’s about playing or betting and timing of the sector.

Unresolved issues --- political investigation of the White House and the Bidens, escalation of the Ukraine war, a Russia on Russia fight and recession - US and global could freezing investors' mood.

 

A return in the sector to the upside: UniQure NV (QURE) popped +$0.31 to $11.45 after Thursday’s -$0.48 or -4.13% to $11.14 after diving Wednesday -$7.82 or -40.23% to $11.62) crashed having unveiled mixed results for its study of a Huntington's disease treatment …   https://www.regmedinvestors.com/articles/13012

 

The top three (3) performing in the session:

·         Friday: Vericel (VCEL) – again, uniQure NV (QURE) and Generation BIO (GBIO)

·         Thursday: Vericel (VCEL) - again, Blueprint Medicine (BPMC) and Intellia Therapeutics (NTLA)

·         Wednesday: Ultragenyx (RARE) – again, Alnylam Pharmaceuticals (ALNY) and Vericel (VCEL)

·         Tuesday: Blueprint Medicine (BPMC), Ultragenyx (RARE) and Voyager Therapeutics (VYGR)

·         Monday: holiday

While The worst three (3) in the session:

·         Friday: Alnylam Pharmaceuticals (ALNY), Sage Therapeutics (SAGE) and Ionis Pharmaceuticals (IONS)

·         Thursday: Alnylam Pharmaceuticals (ALNY), Solid Biosciences (SLDB) and Fate Therapeutics (FATE)

·         Wednesday: uniQure NV (QURE), Intellia Therapeutics (NTLA) and Voyager Therapeutics (VYGR)

·         Tuesday: CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA) and Editas Medicine (EDIT)

·         Monday: holiday

 

WHY (?) do I keep posting, so investors can get a daily update of the sector's share pricing and some individual companies TRUTHS while electronic trading chews on our portfolio edges.

I am definitely considered a contrarian depending on the session – one has to be a watcher of the ups and downs as well as measurer of sentiment. I am also a NO trust investor but, a validate and verify journalist/analyst.

 

The NO spin zone! U.S. public shareholders deserve accountability …

 

Biostage (OTCQB: BSTG) … so many issues from the past as many of those “miscreant management” members are still employed!

Friday closed down -$0.19 with 2,673 shares traded after Thursday closed down -$0.40 with 5,400, Wednesday closed down -$0.12 with 2,676 shares traded, Tuesday closed down -$0.08 with 1,523 shares traded, Monday’s market holiday post last Friday closing down -$0.2175 with 410 shares traded, <3-month average =758 shares>

·         Biostage (OTCQB: BSTG) finally announced a clinical trial initiation for an IND that was approved on 3/20/2020 – what’s with the time (3 years and 2 months) interval?

·         Question: Review the number of shares traded on a weekly and monthly basis … is OTCQB: BSTG a Ponzi scheme (with their pump/promote buy and sell agenda) as shares are bought to replace those sold?

·         Accumulated deficit:  $85,901 M – still NO product in sight – a 4-to-5-year clinical trial BEFORE they can evolve to a pediatric protocol!

·         OTCQB: BSTG is holding their annual meeting on 7/19, to vote the Beijing, China designated directors …??? Certainly NOT a US company ANYMORE!

 

My question that resounds, that should be asked is how many companies are at the end of sentiments …  leash?

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.